Close Menu

NEW YORK (GenomeWeb) – Biocept today priced its public offering of more than 4.9 million shares of common stock at $.68 per share.

Net proceeds from the offering, expected to close on or about Dec. 7, is anticipated to be $3 million, which will go toward working capital and other general corporate purposes, Biocept said. The firm noted that no warrants to purchase shares of its common stock will be issued to investors in connection with the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.